Mebendazole
Mebendazole (MBZ), sold under the brand name Vermox among others, is a medication used to treat a number of parasitic worm infestations. This includes ascariasis, pinworm infection, hookworm infections, guinea worm infections, hydatid disease, and giardia, among others. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Vermox, Ovex, others |
Other names | MBZ |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682315 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 2–10% |
Protein binding | 95% |
Metabolism | Extensive liver |
Elimination half-life | 3–6 hours |
Excretion | Feces, urine (5–10%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.046.017 |
Chemical and physical data | |
Formula | C16H13N3O3 |
Molar mass | 295.298 g·mol−1 |
3D model (JSmol) | |
Melting point | 288.5 °C (551.3 °F) |
| |
| |
(verify) |
Mebendazole is usually well tolerated. Common side effects include headache, vomiting, and ringing in the ears. If used at large doses it may cause bone marrow suppression. It is unclear if it is safe in pregnancy. Mebendazole is a broad-spectrum antihelminthic agent of the benzimidazole type.
Mebendazole came into use in 1971, after it was developed by Janssen Pharmaceutica in Belgium. It is on the World Health Organization's List of Essential Medicines. Mebendazole is available as a generic medication.